S-1: Caring Brands, Inc. Files for IPO to Fuel Wellness Product Expansion

Caring Brands, Inc. aims to raise capital through an initial public offering to support the development and commercialization of its wellness consumer products.

Summary

• Caring Brands, Inc., a wellness consumer products company, has filed a Form S-1 registration statement for an IPO.
• The IPO includes an offering of 750,000 shares of common stock and registration for resale of 6,220,000 shares by selling stockholders.
• The company intends to use the net proceeds for general and working capital purposes, including research and development.
• Caring Brands is developing over-the-counter and cosmetic products, including treatments for hair loss, eczema, psoriasis, and vitiligo, as well as a jellyfish sting protective sunscreen.
• The company's lead product, Photocil, is being prepared for relaunch in the U.S. in 2025.
• The company is also pursuing licensing opportunities in Europe and South America.
• The company's Hair Enzyme Booster (JW-700) is currently being sold in India and the U.S.
• CB-101, a treatment for atopic dermatitis, is undergoing reformulation and is expected to launch in the U.S. in Q4 2025.
• NoStingz, a sunscreen product designed to protect against jellyfish stings, is also being reformulated.
• The company is also exploring market opportunities for the Ebola Rapid Test through a license agreement with NOVODX Corporation.
• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company has submitted an application to list its shares on the NASDAQ under the symbol CABR.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has promising products, it also faces significant financial challenges and risks.

Positives

• The company has a diverse product pipeline targeting large and growing markets.
• The company has existing licensing agreements in place for its products in India.
• The company has a license agreement with Taisho Pharmaceutical Co., Ltd. for the Hair Enzyme Booster in Japan.
• The company has completed clinical trials demonstrating the efficacy of its products.
• The company is pursuing licensing opportunities in Europe and South America.
• The company has a research collaboration and non-exclusive license agreement with NOVODX Corporation for the Ebola Rapid Test.

Negatives

• The company has a limited operating history and has not historically operated as a standalone company.
• The company has a limited operating history as a publicly traded company, and its historical financial information is not necessarily representative of the results it would have achieved as a publicly traded company.
• The company has a working capital deficiency and has had no operations for the period from inception to December 31, 2024.
• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company may not be able to successfully compete against companies with substantially greater resources.
• The company may not be able to access the credit and capital markets at the times and in the amounts needed on acceptable terms.
• The distribution of shares by Safety Shot may result in tax liabilities for Safety Shot and its stockholders.
• The company's Common Stock may come under initial selling pressure as certain Safety Shot stockholders sell their shares.
• The company will bear the incremental costs associated with being a publicly-held company and may need to absorb certain corporate and operational support costs previously provided by Safety Shot.

Risks

• The company may be unable to achieve some or all of the benefits that it expects to achieve from the Separation.
• The company may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as a publicly traded company, and it may experience increased costs after the Separation.
• The distribution, together with certain related transactions, does not qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, Safety Shot and its stockholders could be subject to significant tax liabilities.
• Some of the company's directors and executive officers own Safety Shot common stock or options to acquire Safety Shot common stock and hold positions with Safety Shot, which could cause conflicts of interest, or the appearance of conflicts of interest, that result in the company not acting on opportunities it otherwise may have.
• The company has a limited operating history, which makes it difficult to accurately evaluate its business prospects.
• The company may not have adequate capital to fund its business.
• The company may not be able to successfully compete against companies with substantially greater resources.
• The sale of the company's products involves product liability and related risks that could expose the company to significant insurance and loss expenses.
• Raising additional capital may cause dilution to the company's existing stockholders, restrict its operations or require it to relinquish rights to its technologies or other assets.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• If the company is not able to adequately protect its intellectual property, then it may not be able to compete effectively, and it may not be profitable.
• The company is an emerging growth company and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make its common stock less attractive to investors.
• The company's common stock may become subject to the SECs penny stock rules and accordingly, broker-dealers may experience difficulty in completing customer transactions and trading activity in its securities may be adversely affected.

Future Outlook

The company intends to expand its revenues through a combination of expanding its revenues, with interim cash flow deficiencies being addressed through additional equity and debt financing.

Management Comments

• Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India.
• Management believes that India presents a potential opportunity for market expansion.
• Management believes that these factors may contribute to expanding market opportunities.

Industry Context

The document provides market data for the phototherapy treatment, psoriasis treatment, and vitiligo treatment markets, indicating the potential for growth in these areas.

Comparison to Industry Standards

• The global phototherapy treatment market is projected to rise from ~ USD $1.9 billion in 2023 to ~ USD $3.23 billion by 2033, at a CAGR of around 5.2% during the forecast period from 2023 to 2033, according to Future Market Insights (2023).
• The global psoriasis treatment market was worth ~ $34 billion globally in the 12 months ending June 2023, according to a report by Nature Reviews Drug Discovery (2024).
• The global market is expected to reach ~ USD $54-67 billion by 2030, with a CAGR of 8-10% from 2023 to 2030, according to the same report (Nature Reviews Drug Discovery, 2024).
• The global vitiligo treatment market was valued at ~ USD 538.90 million in 2024, according to a report by Expert Market Research (2024).
• The global market is projected to grow at a CAGR of 4.60% from 2025 to 2034, reaching ~ USD 807.70 million by 2034 (Expert Market Research, 2024).

Related Party Transactions

• On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement with NOVODX Corporation a Delaware corporation and a related party (NOVODX).
• Effective as of the date of the Separation Agreement the Company operates as a separate entity from Safety Shot.
• The terms of the Separation and Exchange Agreement may be more or less favorable to us than if they had been negotiated with unaffiliated third parties.

Stakeholder Impact

• The distribution of shares by Safety Shot may result in tax liabilities for Safety Shot and its stockholders.
• The company's Common Stock may come under initial selling pressure as certain Safety Shot stockholders sell their shares.
• Potential investors will be able to invest directly in the company's business.

Next Steps

• The company plans to apply for a National Drug Code (NDC) number for FDA registration prior to relaunching Photocil in the U.S. market.
• The company intends to complete the reformulation and initiate the stability testing of NoStingz by the second quarter of 2025.
• The company plans to initiate the production run and clinical testing for CB-101 by the fourth quarter of 2025.
• The company intends to complete the reformulation and initiate the stability testing of NoStingz by the second quarter of 2025.
• The company plans to complete the stability testing and initiate the FDA registration process for NoStingz by the fourth quarter of 2025.

Key Dates

Keywords

IPO, wellness, consumer products, Photocil, Hair Enzyme Booster, CB-101, NoStingz, Ebola Rapid Test, licensing, clinical trials, dermatology, psoriasis, vitiligo, hair loss, eczema